- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Medicine
Volume 2012 (2012), Article ID 740603, 5 pages
A Case of Hypogonadotropic Hypogonadism Caused by Opioid Treatment for Nonmalignant Chronic Pain
1Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
2Anesthesiology and Intensive Care, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
3Department of Anesthesiology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino 583-8588, Japan
4Pain Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Received 17 October 2012; Accepted 14 December 2012
Academic Editor: Gerald S. Supinski
Copyright © 2012 Yukiko Tabuchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. M. Gilson, K. M. Ryan, D. E. Joranson, and J. L. Dahl, “A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002,” Journal of Pain and Symptom Management, vol. 28, no. 2, pp. 176–188, 2004.
- R. Abs, J. Verhelst, J. Maeyaert et al., “Endocrine consequences of long-term intrathecal administration of opioids,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 6, pp. 2215–2222, 2000.
- L. J. Roberts, P. M. Finch, P. T. Pullan, C. I. Bhagat, and L. M. Price, “Sex hormone suppression by intrathecal opioids: a prospective study,” Clinical Journal of Pain, vol. 18, no. 3, pp. 144–148, 2002.
- H. W. Daniell, “Hypogonadism in men consuming sustained-action oral opioids,” Journal of Pain, vol. 3, no. 5, pp. 377–384, 2002.
- H. W. Daniell, R. Lentz, and N. A. Mazer, “Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency,” Journal of Pain, vol. 7, no. 3, pp. 200–210, 2006.
- H. W. Daniell, “Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain,” Journal of Pain, vol. 9, no. 1, pp. 28–36, 2008.
- L. A. Fraser, D. Morrison, P. Morley-Forster et al., “Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women,” Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 1, pp. 38–43, 2009.
- A. M. Aloisi, I. Ceccarelli, M. Carlucci, et al., “Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients,” Reproductive Biology and Endocrinology, vol. 9, article 26, 2011.
- A. Rhodin, M. Stridsberg, and T. Gordh, “Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment,” Clinical Journal of Pain, vol. 26, no. 5, pp. 374–380, 2010.
- K. M. Oltmanns, H. L. Fehm, and A. Peters, “Chronic fentanyl application induces adrenocortical insufficiency,” Journal of Internal Medicine, vol. 257, no. 5, pp. 478–480, 2005.
- K. Müssig, D. Knaus-Dittmann, H. Schmidt, K. Mörike, and H. U. Häring, “Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment,” Clinical Endocrinology, vol. 66, no. 4, pp. 604–605, 2007.
- D. E. Moulin, A. J. Clark, M. Speechley, and P. K. Morley-Forster, “Chronic pain in Canada—prevalence, treatment, impact and the role of opioid analgesia,” Pain Research and Management, vol. 7, no. 4, pp. 179–184, 2002.
- H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher, “Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment,” European Journal of Pain, vol. 10, no. 4, pp. 287–333, 2006.
- F. Azizi, A. G. Vagenakis, and C. Longcope, “Decreased serum testosterone concentration in male heroin and methadone addicts,” Steroids, vol. 22, no. 4, pp. 467–472, 1973.
- M. A. Pelosi, J. C. Sama, H. Caterini, and H. A. Kaminetzky, “Galactorrhea-amenorrhea syndrome associated with heroin addiction,” American Journal of Obstetrics and Gynecology, vol. 118, no. 7, pp. 966–970, 1974.
- F. Facchinetti, A. Volpe, and G. Farci, “Hypothalamus-pituitary-adrenal axis of heroin addicts,” Drug and Alcohol Dependence, vol. 15, no. 4, pp. 361–366, 1985.
- N. Bliesener, S. Albrecht, A. Schwager, K. Weckbecker, D. Lichtermann, and D. Klingmüller, “Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 1, pp. 203–206, 2005.
- J. Bang-Ping, “Sexual dysfunction in men who abuse illicit drugs: a preliminary report,” Journal of Sexual Medicine, vol. 6, no. 4, pp. 1072–1080, 2009.
- J. H. Mendelson, J. Ellingboe, B. A. Judson, and A. Goldstein, “Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal,” Clinical Pharmacology and Therapeutics, vol. 35, no. 4, pp. 545–547, 1984.
- G. Woody, A. T. McLellan, C. O'Brien et al., “Hormone secretion in methadone-dependent and abstinent patients,” NIDA Research Monograph Series, no. 81, pp. 216–223, 1988.
- J. H. Mendelson, J. E. Mendelson, and V. D. Patch, “Plasma testosterone levels in heroin addiction and during methadone maintenance,” Journal of Pharmacology and Experimental Therapeutics, vol. 192, no. 1, pp. 211–217, 1975.
- C. Vuong, S. H. M. Van Uum, L. E. O'Dell, K. Lutfy, and T. C. Friedman, “The effects of opioids and opioid analogs on animal and human endocrine systems,” Endocrine Reviews, vol. 31, no. 1, pp. 98–132, 2010.
- T. J. Cicero, “Effects of exogenous and endogenous opiates on the hypothalamic-pituitary-gonadal axis in the male,” Federation Proceedings, vol. 39, no. 8, pp. 2551–2554, 1980.
- J. Ellingboe, J. D. Veldhuis, and J. H. Mendelson, “Effect of endogenous opioid blockade on the amplitude and frequency of pulsatile luteinizing hormone secretion in normal men,” Journal of Clinical Endocrinology and Metabolism, vol. 54, no. 4, pp. 854–857, 1982.
- M. S. Blank and D. L. Roberts, “Antagonist of gonadotropin-releasing hormone blocks naloxone-induced elevations in serum luteinizing hormone,” Neuroendocrinology, vol. 35, no. 5, pp. 309–312, 1982.
- J. D. Veldhuis, A. D. Rogol, E. Samojlik, and N. H. Ertel, “Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man,” Journal of Clinical Investigation, vol. 74, no. 1, pp. 47–55, 1984.
- K. M. Orstead and H. G. Spies, “Inhibition of hypothalamic gonadotropin-releasing hormone release by endogenous opioid peptides in the female rabbit,” Neuroendocrinology, vol. 46, no. 1, pp. 14–23, 1987.
- H. Mehmanesh, O. F. X. Almeida, K. E. Nikolarakis, and A. Herz, “Hypothalamic LH-RH release after acute and chronic treatment with morphine studied in a combined in vivo/in vitro model,” Brain Research, vol. 451, no. 1-2, pp. 69–76, 1988.
- G. R. Graves, T. G. Kennedy, R. F. Weick, and R. F. Casper, “The effect of nalmefene on pulsatile secretion of luteinizing hormone and prolactin in men,” Human Reproduction, vol. 8, no. 10, pp. 1598–1603, 1993.
- T. J. Cicero, R. D. Bell, W. G. Wiest, J. H. Allison, K. Polakoski, and E. Robins, “Function of the male sex organs in heroin and methadone users,” The New England Journal of Medicine, vol. 292, no. 17, pp. 882–887, 1975.
- M. L. Adams, B. Sewing, J. B. Forman, E. R. Meyer, and T. J. Cicero, “Opioid-induced suppression of rat testicular function,” Journal of Pharmacology and Experimental Therapeutics, vol. 266, no. 1, pp. 323–328, 1993.
- T. Kaminski, “The involvement of protein kinases in signalling of opioid agonist FK 33-824 in porcine granulosa cells,” Animal Reproduction Science, vol. 91, no. 1-2, pp. 107–122, 2006.
- V. Chan, C. Wang, and R. T. T. Yeung, “Effects of heroin addiction on thyrotrophin, thyroid hormones and prolactin secretion in men,” Clinical Endocrinology, vol. 10, no. 6, pp. 557–565, 1979.
- G. Delitala, A. Grossman, and G. M. Besser, “The participation of hypothalamic dopamine in morphine-induced prolactin release in man,” Clinical Endocrinology, vol. 19, no. 4, pp. 437–444, 1983.
- Z. Merza, N. Edwards, S. J. Walters, J. Newell-Price, and R. J. M. Ross, “Patients with chronic pain and abnormal pituitary function require investigation,” The Lancet, vol. 361, no. 9376, pp. 2203–2204, 2003.
- N. Katz and N. A. Mazer, “The impact of opioids on the endocrine system,” Clinical Journal of Pain, vol. 25, no. 2, pp. 170–175, 2009.
- H. W. Daniell, “DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production,” Journal of Pain, vol. 7, no. 12, pp. 901–907, 2006.
- H. J. Schneider, G. Aimaretti, I. Kreitschmann-Andermahr, G. K. Stalla, and E. Ghigo, “Hypopituitarism,” The Lancet, vol. 369, no. 9571, pp. 1461–1470, 2007.
- L. J. Forman, V. Tingle, S. Estilow, and J. Cater, “The response to analgesia testing is affected by gonadal steroids in the rat,” Life Sciences, vol. 45, no. 5, pp. 447–454, 1989.
- M. S. Harbuz, Z. Perveen-Gill, S. L. Lightman, and D. S. Jessop, “A protective role for testosterone in adjuvant-induced arthritis,” British Journal of Rheumatology, vol. 34, no. 12, pp. 1117–1122, 1995.
- A. M. Aloisi, I. Ceccarelli, P. Fiorenzani, A. M. De Padova, and C. Massafra, “Testosterone affects formalin-induced responses differently in male and female rats,” Neuroscience Letters, vol. 361, no. 1–3, pp. 262–264, 2004.
- T. Taylor, R. G. Dluhy, and G. H. Williams, “β-Endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 57, no. 3, pp. 592–596, 1983.
- B. Allolio, U. Deuss, and D. Kaulen, “FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease,” Journal of Clinical Endocrinology and Metabolism, vol. 63, no. 6, pp. 1427–1431, 1986.
- R. Hallinan, A. Byrne, K. Agho, C. McMahon, P. Tynan, and J. Attia, “Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment,” Journal of Sexual Medicine, vol. 5, no. 3, pp. 684–692, 2008.